Award
National Cancer Institute 5UG3CA301294-02
Engineered probiotic bacteria for colorectal cancer immunoprevention and interception
Recipient
Columbia University Health Sciences
Award Amount
$727,904.00
Ceiling
$727,904.00
Awarded
June 11, 2026
Identifier
5UG3CA301294-02
Award to Columbia University Health Sciences to develop engineered probiotic bacteria as immunotherapies for colorectal cancer prevention and interception, focusing on E. coli Nissle 1917 strains and immune response in mouse models.
Description
This project aims to engineer probiotic bacteria, E. coli Nissle 1917 (EcN), to identify and target precancerous lesions in colorectal cancer (CRC). The focus is on characterizing EcN colonization and immune response in a tamoxifen-inducible mouse model of CRC, and designing immunomodulatory EcN strains for CRC prevention and interception. The goal is to develop probiotic-based immunotherapies to prevent and halt CRC progression.